Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration

Gradual DNAm changes were found to align with progression of MASLD and EAA, with EAA a potential nonbiased quantitative biomarker for MASLD. Integrative analysis highlighted potential new therapeutic transcription factor targets, with special emphasis on AEBP1 and emerging nuclear receptors including CAR(NR1I3), MR(NR3C2), GR(NR3C1), and ESRRG, underscoring the potential of epigenetic redox-metabolic therapies for MASLD.

Authors

Institutions

Publication Details

Journal
Clinical Epigenetics
Published
2025-08-04
DOI
https://doi.org/10.1186/s13148-025-01945-6
Citations
2
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration

Guy Van Camp, Wim Vanden Berghe, Erik Fransén, Wim Van Hul et al.
2 citations
Clinical Epigenetics
Liver Disease Diagnosis and Treatment
2.71
article

Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration

Guy Van Camp, Wim Vanden Berghe, Erik Fransén, Wim Van Hul, Evelien Van Dijck, An Verrijken, Steven Timmermans, Emilie Logie, Ligia Mateiu, Sven Francque, Joe Ibrahim, Steven Van Laere, Timothy James Kendall, Jonathan Andrew Fallowfield, Claude Libert, Luc Van Gaal
article en
2 citations

Abstract

Gradual DNAm changes were found to align with progression of MASLD and EAA, with EAA a potential nonbiased quantitative biomarker for MASLD. Integrative analysis highlighted potential new therapeutic transcription factor targets, with special emphasis on AEBP1 and emerging nuclear receptors including CAR(NR1I3), MR(NR3C2), GR(NR3C1), and ESRRG, underscoring the potential of epigenetic redox-metabolic therapies for MASLD.

Clinical EpigeneticsVol. 17(1)
University of Antwerp (BE), Vlaams Instituut voor Biotechnologie (BE), Ghent University (BE), Antwerp University Hospital (BE), VIB-UGent Center for Inflammation Research (BE), Centre for Inflammation Research (GB), University of Edinburgh (GB)
European Commission, Fonds Wetenschappelijk Onderzoek, Universiteit Antwerpen, Vlaamse regering, Innovate UK
Good health and well-being
Openalex Percentile: Top 9%
Liver Disease Diagnosis and Treatment
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.